7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
申请人:Defossa Elisabeth
公开号:US20050182085A1
公开(公告)日:2005-08-18
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof.
The invention relates to compounds of the formula I
in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
申请人:Sanofi-Aventis Deutschland GmbH,
公开号:US07402674B2
公开(公告)日:2008-07-22
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof.
The invention relates to compounds of the formula I
in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
[DE] 7-PHENYLAMINO-4-CHINOLON-3-CARBONSÄURE-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] 7-PHENYLAMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS<br/>[FR] DERIVES D'ACIDE 7-PHENYLAMINO-4-QUINOLONE-3-CARBOXYLIQUE, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION COMME MEDICAMENTS
申请人:AVENTIS PHARMA GMBH
公开号:WO2005073229A1
公开(公告)日:2005-08-11
Die Erfindung betrifft 7-Phenylamino-4-chinolon-3-carbonsäure-Derivate sowie deren physiologisch verträgliche Salze und physiologisch funktionelle Derivate. Die Erfindung betrifft Verbindungen der Formel (I), worin die Reste die angegebenen Bedeutungen haben, sowie deren physiologisch verträgliche Salze. Die Verbindungen eignen sich z.B. als Medikamente zur Prävention und Behandlung von Diabetes Typ 2.